Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries

• Raquel Abad ,

  * E-mail: rabad@isciii.es

  Affiliation Reference Laboratory for Meningococci, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

  ⨯
• Verónica Medina,

  Affiliation Reference Laboratory for Meningococci, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

  ⨯
• Maria Stella,

  Affiliation Novartis Vaccines and diagnostics, a GSK Company, Siena, Italy

  ⨯
• Giuseppe Boccadifuoco,

  Affiliation Novartis Vaccines and diagnostics, a GSK Company, Siena, Italy

  ⨯
• Maurizio Comanducci,

  Affiliation Novartis Vaccines and diagnostics, a GSK Company, Siena, Italy

  ⨯
• Stefania Bambini,

  Affiliation Novartis Vaccines and diagnostics, a GSK Company, Siena, Italy

  ⨯
• Alessandro Muzzi,

  Affiliation Novartis Vaccines and diagnostics, a GSK Company, Siena, Italy

  ⨯
• Julio A. Vázquez

  Affiliation Reference Laboratory for Meningococci, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

  ⨯